Skip to content

Isomorphic Labs

Isomorphic Labs builds predictive and generative AI models for drug discovery, aiming to accelerate scientific breakthroughs and develop life-changing medicines.

30

Overview

Isomorphic Labs is a research-driven company using artificial intelligence to transform drug discovery, with the goal of accelerating breakthroughs and developing life-changing medicines. Founded by Sir Demis Hassabis, the company builds on the Nobel-winning AlphaFold system to create predictive and generative AI models that model complex biological phenomena.

Building on AlphaFold's Legacy

Isomorphic Labs extends the work of AlphaFold, which solved the decades-old challenge of protein structure prediction. The company's name reflects a belief in an underlying symmetry between biology and information science. By harnessing AI, Isomorphic Labs aims to model biological systems with enough fidelity to design novel molecules and anticipate how drugs will perform in the body.

Predictive and Generative AI Models

The company's interdisciplinary team of drug discovery experts and machine learning specialists has developed powerful new AI models. These models are designed to accelerate scientific discovery at digital speed, moving beyond traditional trial-and-error approaches. The focus is on digital biology—using computation to simulate and predict biological outcomes before committing to expensive laboratory experiments.

A Mission to Solve All Disease

Isomorphic Labs has set an ambitious mission: to one day solve all disease with the help of AI. While that goal remains distant, the company frames its work as part of a new era in drug discovery. Every breakthrough, according to the company, brings the promise of digital biology closer to reality. This mission-driven approach attracts talent and partners who share the vision of using AI for human health.

Partnerships and Collaboration

Isomorphic Labs works with pharmaceutical partners to apply its AI models to real-world drug discovery challenges. The company has also joined the Virtual Biology Initiative, which aims to build foundational data for AI models to predict and treat disease. These collaborations suggest a strategy of integrating with the broader life sciences ecosystem rather than operating in isolation.

Leadership and Team

Sir Demis Hassabis, founder and CEO, has stated that there is no more important application for AI than improving human health. The company's leadership includes experts from both drug discovery and machine learning, reflecting its interdisciplinary approach. Isomorphic Labs is hiring across multiple roles, indicating ongoing growth and investment in its research capabilities.

The Road Ahead

Isomorphic Labs operates in a complex and highly regulated field where scientific validation takes years. The company has not yet brought a drug to market, and its AI models are still being developed and tested. Success will depend on whether its predictive and generative models can consistently produce viable drug candidates that succeed in clinical trials. For now, Isomorphic Labs represents a significant bet that AI can reshape one of the most challenging and costly areas of science.

Core features

  • Predictive and generative AI models for drug discovery
  • Builds on the AlphaFold system
  • Interdisciplinary team of drug discovery experts and machine learning specialists
  • Focus on digital biology and modeling complex biological phenomena
  • Aims to design novel molecules and anticipate drug performance
  • Partnerships with pharmaceutical companies

Use cases

  1. 1Accelerating identification of novel drug candidates
  2. 2Predicting how drugs will perform in biological systems
  3. 3Modeling complex biological phenomena to inform drug design
  4. 4Developing innovative medicines for devastating diseases
  5. 5Collaborating with pharmaceutical partners on drug discovery programs

Strengths and things to check

Strengths

  • Leverages Nobel-winning AlphaFold technology
  • Combines deep expertise in drug discovery and machine learning
  • Mission-driven focus on solving all disease
  • Partnerships with leading pharmaceutical companies

Things to check

  • No public product or pricing details available
  • Technology is still in development and not commercially available
  • Success depends on long-term research and validation

Pricing

Subscription pricing is not listed.

Basic information

Added
Oct 10, 2026
Platforms
Web
Chinese & English
Not marked
API
Marked as supported
Self-hosting
Not marked
Best for
Pharmaceutical researchers, biotech companies, and drug discovery teams seeking AI-driven approaches to accelerate therapeutic development.
Information updated
Oct 14, 2026
Website status
Checking
Corrections · Privacy · Data requests?
Contact us

Features, pricing and availability may change. Always verify details on the official website. Maintained by steven · Last updated Oct 14, 2026 →

Related tools

All categories

NeuroFlow

Enterprise Grade

NeuroFlow is a behavioral health analytics and engagement platform for payers, health systems, and federal agencies that need to surface hidden risk, route members to care, and measure outcomes at population scale.

Enterprise GradeAPI Available
60
PaidSOC 2
View details

Nabla

Enterprise Grade

Nabla is a clinical AI layer that captures patient-clinician conversations and generates structured notes, dictation, and coding suggestions inside Epic and major EHRs.

Enterprise GradeAPI Available
60
Free TierSOC 2
View details